Search for content, post, videos

Promising preclinical mRNA vaccine data from Evaxion

Evaxion Biotech and Pantherna Therapeutics have announced preclinical proof of concept for the combination of the two companies’ key technologies. The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to c
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.